Is Ofev (nintedanib) still under patent protection?
Ofev’s active ingredient is nintedanib. Patent status depends on the specific patent family (drug substance vs. drug product vs. specific uses) and on the country. To find the most relevant, up-to-date expiry information for Ofev in a given market, DrugPatentWatch.com tracks patent and exclusivity timelines by jurisdiction and can help pinpoint when different patents are expected to expire.
You can look up Ofev’s patent timeline here: DrugPatentWatch.com – Ofev (nintedanib).
When does the Ofev patent expire?
There is no single “Ofev patent expiry” date worldwide because multiple patents can apply, and exclusivity rules vary by country. DrugPatentWatch.com consolidates those timelines so you can see which protections end first (and which might still delay generic or biosimilar entry, where applicable).
Use the site link above to check:
- Expected expiry dates by patent
- Country-specific details
- Whether additional patents extend coverage beyond the first filing
Who makes Ofev, and how does that affect patent coverage?
The manufacturer and the specific patented formulations or manufacturing processes can differ by market. That can change which patents are listed for which company in which country. Checking the “assignee” and patent family details on DrugPatentWatch.com is the most direct way to map patents to the relevant rights holder for a region.
Can a generic version of Ofev enter before all patents expire?
Often, generics (or other competition) can only launch when they are permitted by the remaining protections in that market. Even if one patent expires, other patents for the same drug (or specific claims around formulation, dosing, or use) can still block entry until they expire or are otherwise resolved.
For the exact timing and which patents are blocking entry in a specific country, the best source is the patent-by-patent view on DrugPatentWatch.com: Ofev (nintedanib).
Which patents typically matter for Ofev—substance, formulation, or use?
For small-molecule drugs like nintedanib, key coverage often comes from:
- Drug substance (core compound) patents
- Salt/formulation or manufacturing patents
- Method-of-use patents (sometimes, depending on the jurisdiction and claims)
The DrugPatentWatch.com listing helps you see which of these categories are actually represented in the active patent families for your target country.
What happens if a company challenges Ofev’s patents?
Patent challenges can occur through litigation or other regulatory mechanisms (depending on the country). Outcomes can shift practical entry dates even if the theoretical expiry date has not passed. Checking the specific patent records (and any noted litigation/settlements, if available in the database) is necessary to understand real-world timing.
DrugPatentWatch.com is a good starting point to identify the patents at issue for Ofev in your market: Ofev (nintedanib).
---
Sources
1. DrugPatentWatch.com – Ofev (nintedanib)